Business UpdateMay 1, 2026, 09:15 AM
NSRX Management to Attend Investor Conferences
AI Summary
Nasus Pharma Ltd. announced that its Chief Financial Officer, Eyal Rubin, will participate in upcoming investor conferences. He is scheduled for 1x1 meetings at the Market Movers Investor Summit on May 5, 2026, and the D. Boral Capital Global Conference on May 7, 2026, both in New York, NY. The company is a clinical-stage pharmaceutical firm developing intranasal powder products for acute medical conditions.
Key Highlights
- CFO Eyal Rubin to participate in 1x1 meetings at the Market Movers Investor Summit on May 5, 2026, in New York, NY.
- CFO Eyal Rubin to participate in 1x1 meetings at the D. Boral Capital Global Conference on May 7, 2026, in New York, NY.
- Nasus Pharma is a clinical-stage pharmaceutical company focused on innovative intranasal products.
- The company is developing NS002, an intranasal powder Epinephrine product for anaphylaxis.
- Nasus Pharma utilizes proprietary powder-based intranasal (PBI) technology for rapid drug delivery.
Price Impact
More from NSRX